iVascular’s ANGIODAPT Trial Completes Enrollment

February 2, 2026—iVascular announced the completion of patient recruitment for the ANGIODAPT trial, which is evaluating ischemic and bleeding outcomes after implantation of the iVascular Angiolite drug-eluting stent and abbreviated dual antiplatelet therapy (DAPT).

According to the company, ANGIODAPT is a two-by-two factorial, all-comer, multicenter, randomized controlled trial. A total of 2,312 patients were enrolled across 38 sites in Spain, Belgium, and France. Initiation of the ANGIODAPT trial was announced in December 2023.

As stated in iVascular’s press release, patients with coronary artery disease were first randomized into two groups based on device (Angiolite vs Xience [Abbott]) and subsequently into two groups according to antiplatelet treatment strategy (abbreviated DAPT vs standard-of-care DAPT).

The study includes two coprimary endpoints: target lesion failure at 1 year (noninferiority test between Angiolite and Xience) and clinically relevant bleeding at 1 year (superiority test for abbreviated DAPT vs standard DAPT). A key secondary endpoint will assess ischemic events between both antiplatelet strategies (tested for noninferiority).

Manel Sabaté, MD, of the Hospital Clinic Barcelona in Barcelona, Spain, serves as Lead Global Scientific Coordinator of the trial.

“The main purpose of the ANGIODAPT trial is to assess the safety and efficacy of the Angiolite stent compared to Xience stent family and demonstrate that an abbreviated DAPT may reduce bleeding events compared to a standard of care regimen without increasing the risk of ischemic events,” commented Dr. Sabaté in the iVascular press release. “Completing recruitment in such a large-scale trial brings us closer to answering questions for daily clinical practice.”